Collegium Pharmaceutical, Inc. to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Collegium Pharmaceutical will report Q3 2025 financial results on November 6, followed by a conference call at 8:00 a.m. ET.

Quiver AI Summary

Collegium Pharmaceutical, Inc. will announce its third quarter 2025 financial results on November 6, 2025, before the market opens. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET, which can be accessed via phone or through the Investors section of its website. Collegium, headquartered in Stoughton, Massachusetts, focuses on enhancing the lives of individuals with serious medical conditions, offering a strong portfolio in pain management and a growing neuropsychiatry business led by its ADHD treatment, Jornay PM. The company emphasizes disciplined capital deployment as part of its growth strategy. For more details, interested parties can visit their website or reach out to their investor relations contacts.

Potential Positives

Collegium Pharmaceutical is scheduled to report its third quarter 2025 financial results, indicating a commitment to transparency and regular communication with investors.
The company will host a live conference call and webcast, providing an opportunity for direct engagement with investors and stakeholders.
Collegium is positioning itself as a leader in responsible pain management and neuropsychiatry, highlighting the potential for growth in its specialized portfolio.
The mention of Jornay PM® as a key growth driver emphasizes the company’s focus on innovative treatments in high-demand therapeutic areas.

Potential Negatives

Failure to provide forward-looking guidance in the announcement may raise concerns among investors regarding future performance.
Dependence on Jornay PM as the lead growth driver could pose risks if competition increases or if the product does not meet growth expectations.
Scheduling the earnings call before market opening may limit investor attention and engagement compared to a more favorable time slot.

FAQ

When will Collegium Pharmaceutical report its third quarter 2025 financial results?

Collegium Pharmaceutical will report its third quarter 2025 financial results on November 6, 2025, before the market opens.

How can I access the Collegium Pharmaceutical earnings call?

You can access the earnings call by dialing (877) 407-8037 for U.S. calls or (201) 689-8037 for international calls.

What time is the Collegium Pharmaceutical Q3 earnings call scheduled?

The Collegium Pharmaceutical Q3 earnings call is scheduled for 8:00 a.m. ET on November 6, 2025.

Where can I find the audio webcast for the earnings call?

The audio webcast will be available in the Investors section of Collegium's website after the earnings call.

What key products is Collegium Pharmaceutical known for?

Collegium is known for its portfolio of responsible pain management medications and Jornay PM®, a treatment for ADHD.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$COLL Insider Trading Activity

$COLL insiders have traded $COLL stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $COLL stock by insiders over the last 6 months:

CAPITAL MANAGEMENT LP RUBRIC sold 25,000 shares for an estimated $946,250
SCOTT DREYER (EVP & Chief Commercial Officer) has made 0 purchases and 2 sales selling 21,250 shares for an estimated $811,052.
THOMAS B SMITH (EVP and Chief Medical Officer) sold 17,478 shares for an estimated $671,576
JOHN GORDON FREUND has made 0 purchases and 2 sales selling 18,260 shares for an estimated $602,789.
GINO SANTINI sold 5,405 shares for an estimated $201,018

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$COLL Hedge Fund Activity

We have seen 105 institutional investors add shares of $COLL stock to their portfolio, and 118 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

MILLENNIUM MANAGEMENT LLC removed 423,860 shares (-65.4%) from their portfolio in Q2 2025, for an estimated $12,533,540
CITADEL ADVISORS LLC removed 269,999 shares (-52.9%) from their portfolio in Q2 2025, for an estimated $7,983,870
J. GOLDMAN & CO LP added 243,448 shares (+inf%) to their portfolio in Q2 2025, for an estimated $7,198,757
QUANTEDGE CAPITAL PTE LTD removed 237,755 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,030,415
EXODUSPOINT CAPITAL MANAGEMENT, LP removed 196,491 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,810,238
RUBRIC CAPITAL MANAGEMENT LP added 157,743 shares (+5.3%) to their portfolio in Q2 2025, for an estimated $4,664,460
LOOMIS SAYLES & CO L P added 149,766 shares (+79.9%) to their portfolio in Q2 2025, for an estimated $4,428,580

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$COLL Analyst Ratings

Wall Street analysts have issued reports on $COLL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 08/11/2025

To track analyst ratings and price targets for $COLL, check out Quiver Quantitative's $COLL forecast page.

$COLL Price Targets

Multiple analysts have issued price targets for $COLL recently. We have seen 2 analysts offer price targets for $COLL in the last 6 months, with a median target of $40.5.

Here are some recent targets:

Brandon Folkes from HC Wainwright & Co. set a target price of $44.0 on 08/11/2025
David Amsellem from Piper Sandler set a target price of $37.0 on 05/09/2025

Full Release

STOUGHTON, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

Conference Call Information
To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2025 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com .

Investor Contacts:
Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]